U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C20H18O10
Molecular Weight 418.3509
Optical Activity ( + / - )
Additional Stereochemistry Yes
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0
Stereo Comments AXIAL, RACEMIC

SHOW SMILES / InChI
Structure of BIFENDATE

SMILES

COC(=O)C1=CC(OC)=C2OCOC2=C1C3=C(C=C(OC)C4=C3OCO4)C(=O)OC

InChI

InChIKey=JMZOMFYRADAWOG-UHFFFAOYSA-N
InChI=1S/C20H18O10/c1-23-11-5-9(19(21)25-3)13(17-15(11)27-7-29-17)14-10(20(22)26-4)6-12(24-2)16-18(14)30-8-28-16/h5-6H,7-8H2,1-4H3

HIDE SMILES / InChI

Description

Bifendate is a synthetic intermediate of Schisandrin C and also an anti-HBV drug used in Chinese medicine for the treatment of chronic hepatitis B. Following the intake of Bifendate in rats, the drug was observed to improve liver function by increasing the detoxification process, reducing pathological lesions, and accelerating hepatocyte regeneration. Bifendate can also function as a membrane-stabilizing agent to protect the cell from damage. After treatment with Bifendate, the protein metabolic processes of hepatitis patients were improved, with increased serum albumin levels and decreased globulin levels. Bifendate is a potent inducer of cytochrome proteins (CYPs) and can result in clinically significant interactions. It has been proposed that the increased detoxification capability of Bifendate originates from an increase in the level of P450. Bifendate may function as a protecting agent to prevent drug-induced liver dysfunction by increasing the activity of CYP450.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
30- 67.5 mg/d for up to 12 months
Route of Administration: Oral
In Vitro Use Guide
1 x 10^4 K562 and K562/A02 cells were grown in 96-well microtiter plates and incubated for 24 h. Various concentrations of compounds (Bifendate, 100mkM) diluted with medium were added into the wells. And the exponentially growing cancer cells were incubated for 72 h at 37 C (5% CO2, 95% humidity). Then, MTS was added directly to the cells. After additional incubation for 3 h at 37 C, the absorbance at 490 nm was read on a microplate reader (Thermo, USA).